Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 21;369(6506):1014-1018.
doi: 10.1126/science.abd0831. Epub 2020 Jun 15.

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Alina Baum  1 , Benjamin O Fulton  1 , Elzbieta Wloga  1 , Richard Copin  1 , Kristen E Pascal  1 , Vincenzo Russo  1 , Stephanie Giordano  1 , Kathryn Lanza  1 , Nicole Negron  1 , Min Ni  1 , Yi Wei  1 , Gurinder S Atwal  1 , Andrew J Murphy  1 , Neil Stahl  1 , George D Yancopoulos  1 , Christos A Kyratsous  2
Affiliations

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Alina Baum et al. Science. .

Abstract

Antibodies targeting the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) present a promising approach to combat the coronavirus disease 2019 (COVID-19) pandemic; however, concerns remain that mutations can yield antibody resistance. We investigated the development of resistance against four antibodies to the spike protein that potently neutralize SARS-CoV-2, individually as well as when combined into cocktails. These antibodies remain effective against spike variants that have arisen in the human population. However, novel spike mutants rapidly appeared after in vitro passaging in the presence of individual antibodies, resulting in loss of neutralization; such escape also occurred with combinations of antibodies binding diverse but overlapping regions of the spike protein. Escape mutants were not generated after treatment with a noncompeting antibody cocktail.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1. Escape mutant screening protocol.
(A) A schematic is displayed of the VSV-SARS-CoV-2-S virus genome encoding residues 1-1255 of the spike protein in place of the VSV glycoprotein. N, nucleoprotein, P, phosphoprotein, M, matrix, and L, large polymerase. (B) A total of 1.5 × 106 pfu of the parental VSV-SARS-CoV-2-S virus was passed in the presence of antibody dilutions for 4 days on Vero E6 cells. Cells were screened for virus replication by monitoring for virally induced cytopathic effect (CPE). Supernatants and cellular RNAs were collected from wells under the greatest antibody selection with detectable viral replication (circled wells; ≥20% CPE). For a second round of selection, 100uL of the P1 supernatant was expanded for 4 days under increasing antibody selection in fresh Vero E6 cells. RNA was collected from the well with the highest antibody concentration with detectable viral replication. The RNA was deep sequenced from both passages to determine the selection of mutations resulting in antibody escape. (C) The passaging results of the escape study are presented with the qualitative percentage of CPE observed in each dilution (red ≥ 20%CPE and blue < 20% CPE). Black boxes indicate dilutions that were passaged and sequenced in P1 or sequenced in P2. A no antibody control was sequenced from each passage to monitor for tissue culture adaptations.
Fig. 2
Fig. 2. Deep sequencing of passaged virus identifies escape mutations.
VSV-SARS-CoV-2-S virus was mixed with either individual or combinations of anti-spike mAbs. Viral RNA from wells with the highest mAb concentration and detectable cytopathic effect (CPE) on passage 1 or 2 (collected 4 days post-infection) was isolated and RNAseq analysis was performed to identify changes in spike protein sequence relative to input virus. For passage 2, viral RNA was isolated and sequenced from wells with high mAb concentrations (>10ug/ml) with subsequently validated escape; if no validated escape was seen at these high mAb concentrations and no virus was grown, ND is shown as no virus RNA was isolated. All mutated amino acid residues within the spike protein are shown. Specific condition (concentration in ug/ml) of the well that was selected for sequencing is shown in the left-hand column (refer to Fig. 1 for outline of the experiment). Red boxes highlight residues that were mutated relative to input virus under each condition specified in the left-hand column. Percentage in each box identifies % of sequencing reads that contained the respective mutant sequence. Residues mapping to the RBD domain are highlighted in blue.
See this image and copyright information in PMC

Similar articles

  • Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail.
    Hansen J, Baum A, Pascal KE, Russo V, Giordano S, Wloga E, Fulton BO, Yan Y, Koon K, Patel K, Chung KM, Hermann A, Ullman E, Cruz J, Rafique A, Huang T, Fairhurst J, Libertiny C, Malbec M, Lee WY, Welsh R, Farr G, Pennington S, Deshpande D, Cheng J, Watty A, Bouffard P, Babb R, Levenkova N, Chen C, Zhang B, Romero Hernandez A, Saotome K, Zhou Y, Franklin M, Sivapalasingam S, Lye DC, Weston S, Logue J, Haupt R, Frieman M, Chen G, Olson W, Murphy AJ, Stahl N, Yancopoulos GD, Kyratsous CA. Hansen J, et al. Science. 2020 Aug 21;369(6506):1010-1014. doi: 10.1126/science.abd0827. Epub 2020 Jun 15. Science. 2020. PMID: 32540901 Free PMC article.
  • Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.
    Liu L, Wang P, Nair MS, Yu J, Rapp M, Wang Q, Luo Y, Chan JF, Sahi V, Figueroa A, Guo XV, Cerutti G, Bimela J, Gorman J, Zhou T, Chen Z, Yuen KY, Kwong PD, Sodroski JG, Yin MT, Sheng Z, Huang Y, Shapiro L, Ho DD. Liu L, et al. Nature. 2020 Aug;584(7821):450-456. doi: 10.1038/s41586-020-2571-7. Epub 2020 Jul 22. Nature. 2020. PMID: 32698192
  • Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
    Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi S, Jaconi S, Culap K, Zatta F, De Marco A, Peter A, Guarino B, Spreafico R, Cameroni E, Case JB, Chen RE, Havenar-Daughton C, Snell G, Telenti A, Virgin HW, Lanzavecchia A, Diamond MS, Fink K, Veesler D, Corti D. Pinto D, et al. Nature. 2020 Jul;583(7815):290-295. doi: 10.1038/s41586-020-2349-y. Epub 2020 May 18. Nature. 2020. PMID: 32422645
  • Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies.
    Hussain A, Hasan A, Nejadi Babadaei MM, Bloukh SH, Chowdhury MEH, Sharifi M, Haghighat S, Falahati M. Hussain A, et al. Biomed Pharmacother. 2020 Oct;130:110559. doi: 10.1016/j.biopha.2020.110559. Epub 2020 Aug 1. Biomed Pharmacother. 2020. PMID: 32768882 Free PMC article. Review.
  • Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions.
    Gavor E, Choong YK, Er SY, Sivaraman H, Sivaraman J. Gavor E, et al. Trends Immunol. 2020 Nov;41(11):1006-1022. doi: 10.1016/j.it.2020.09.004. Epub 2020 Sep 17. Trends Immunol. 2020. PMID: 33041212 Free PMC article. Review.
See all similar articles

Cited by

  • COVID-19-vaccinated plasma treatment for COVID-19 patients?
    Alberca GGF, Alberca RW. Alberca GGF, et al. Influenza Other Respir Viruses. 2021 Jul;15(4):552-553. doi: 10.1111/irv.12852. Epub 2021 Mar 14. Influenza Other Respir Viruses. 2021. PMID: 33715284 Free PMC article. No abstract available.
  • Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines.
    Focosi D, Maggi F. Focosi D, et al. Rev Med Virol. 2021 Nov;31(6):e2231. doi: 10.1002/rmv.2231. Epub 2021 Mar 16. Rev Med Virol. 2021. PMID: 33724631 Free PMC article. Review.
  • Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants.
    Ikegame S, Siddiquey MNA, Hung CT, Haas G, Brambilla L, Oguntuyo KY, Kowdle S, Vilardo AE, Edelstein A, Perandones C, Kamil JP, Lee B. Ikegame S, et al. Res Sq [Preprint]. 2021 Apr 8:rs.3.rs-400230. doi: 10.21203/rs.3.rs-400230/v1. Res Sq. 2021. Update in: Nat Commun. 2021 Jul 26;12(1):4598. doi: 10.1038/s41467-021-24909-9. PMID: 33851150 Free PMC article. Updated. Preprint.
  • Antibody evasion by the P.1 strain of SARS-CoV-2.
    Dejnirattisai W, Zhou D, Supasa P, Liu C, Mentzer AJ, Ginn HM, Zhao Y, Duyvesteyn HME, Tuekprakhon A, Nutalai R, Wang B, López-Camacho C, Slon-Campos J, Walter TS, Skelly D, Costa Clemens SA, Naveca FG, Nascimento V, Nascimento F, Fernandes da Costa C, Resende PC, Pauvolid-Correa A, Siqueira MM, Dold C, Levin R, Dong T, Pollard AJ, Knight JC, Crook D, Lambe T, Clutterbuck E, Bibi S, Flaxman A, Bittaye M, Belij-Rammerstorfer S, Gilbert SC, Carroll MW, Klenerman P, Barnes E, Dunachie SJ, Paterson NG, Williams MA, Hall DR, Hulswit RJG, Bowden TA, Fry EE, Mongkolsapaya J, Ren J, Stuart DI, Screaton GR. Dejnirattisai W, et al. Cell. 2021 May 27;184(11):2939-2954.e9. doi: 10.1016/j.cell.2021.03.055. Epub 2021 Mar 30. Cell. 2021. PMID: 33852911 Free PMC article.
  • Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.
    Piccoli L, Park YJ, Tortorici MA, Czudnochowski N, Walls AC, Beltramello M, Silacci-Fregni C, Pinto D, Rosen LE, Bowen JE, Acton OJ, Jaconi S, Guarino B, Minola A, Zatta F, Sprugasci N, Bassi J, Peter A, De Marco A, Nix JC, Mele F, Jovic S, Rodriguez BF, Gupta SV, Jin F, Piumatti G, Lo Presti G, Pellanda AF, Biggiogero M, Tarkowski M, Pizzuto MS, Cameroni E, Havenar-Daughton C, Smithey M, Hong D, Lepori V, Albanese E, Ceschi A, Bernasconi E, Elzi L, Ferrari P, Garzoni C, Riva A, Snell G, Sallusto F, Fink K, Virgin HW, Lanzavecchia A, Corti D, Veesler D. Piccoli L, et al. Cell. 2020 Nov 12;183(4):1024-1042.e21. doi: 10.1016/j.cell.2020.09.037. Epub 2020 Sep 16. Cell. 2020. PMID: 32991844 Free PMC article.
See all "Cited by" articles

References

    1. Yan R., Zhang Y., Li Y., Xia L., Guo Y., Zhou Q., Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367, 1444–1448 (2020). 10.1126/science.abb2762 - DOI - PMC - PubMed
    1. Wang Q., Zhang Y., Wu L., Niu S., Song C., Zhang Z., Lu G., Qiao C., Hu Y., Yuen K.-Y., Wang Q., Zhou H., Yan J., Qi J., Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell 181, 894–904.e9 (2020). 10.1016/j.cell.2020.03.045 - DOI - PMC - PubMed
    1. Hansen J., Baum A., Pascal K. E., Russo V., Giordano S., Wloga E., Fulton B. O., Yan Y., Koon K., Patel K., Chung K. M., Herman A., Ullman E., Cruz J., Rafique A., Huang T., Fairhurst J., Libertiny C., Malbec M., Lee W.-y., Welsh R., Farr G., Pennington S., Deshpande D., Cheng J., Watty A., Bouffard P., Babb R., Levenkova N., Chen C., Zhang B., Romero Hernandez A., Saotome K., Zhou Y., Franklin M., Sivapalasingam S., Chien Lye D., Weston S., Logue J., Haupt R., Frieman M., Chen G., Olson W., Murphy A. J., Stahl N., Yancopoulos G. D., Kyratsous C. A., Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 10.1126/science.abd0827 (2020). 10.1126/science.abd0827 - DOI - PMC - PubMed
    1. Lau S.-Y., Wang P., Mok B. W.-Y., Zhang A. J., Chu H., Lee A. C.-Y., Deng S., Chen P., Chan K.-H., Song W., Chen Z., To K. K.-W., Chan J. F.-W., Yuen K.-Y., Chen H., Attenuated SARS-CoV-2 variants with deletions at the S1/S2 junction. Emerg. Microbes Infect. 9, 837–842 (2020). 10.1080/22221751.2020.1756700 - DOI - PMC - PubMed
    1. Dieterle M. E., Haslwanter D., Bortz R. H. 3rd, Wirchnianski A. S., Lasso G., Vergnolle O., Abbasi S. A., Fels J. M., Laudermilch E., Florez C., Mengotto A., Kimmel D., Malonis R. J., Georgiev G., Quiroz J., Barnhill J., Pirofski L. A., Daily J. P., Dye J. M., Lai J. R., Herbert A. S., Chandran K., Jangra R. K., A replication-competent vesicular stomatitis virus for studies of SARS-CoV-2 spike-mediated cell entry and its inhibition. bioRxiv (2020). - PMC - PubMed

Publication types

MeSH terms